Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Basaglar

- PMLiVE

Lilly signs $1.25bn collaboration deal with MiNA Therapeutics

Lilly will pay MiNA $25m upfront as well as milestones payments of up to a total of $245m per target

- PMLiVE

US backs proposal to waive IP protection for COVID-19 vaccines

"Monumental decision" could see IP protections for COVID-19 vaccines temporarily removed

- PMLiVE

Eli Lilly/AbCellera’s COVID-19 variant-targeting antibody enters clinical trials

Drug will be evaluted alone and together with other monoclonal antibodies in the expanded BLAZE-4 trial

- PMLiVE

Lilly cuts 2021 guidance to reflect ‘lower expected revenue’ from COVID-19 antibody sales

FDA recently removed emergency authorisation for bamlanivimab monotherapy

- PMLiVE

AZ, Sanofi’s nirsevimab hits primary endpoint in RSV trial

Drug reduced lower respiratory tract infections caused by respiratory syncytial virus in infants

- PMLiVE

Second Sarclisa combination regimen for multiple myeloma approved in EU

Second indication for Sarclisa covers drug’s use in combination with another standard myeloma treatment

- PMLiVE

Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US

Decision prompted by the ‘evolving variant landscape’ in the US

- PMLiVE

Lilly’s RET inhibitor Retevmo shows early promise in new cancer types

Trial included patients with pancreatic, colon, breast and salivary cancer

- PMLiVE

Sanofi pays $160m upfront to acquire Tidal Therapeutics

French pharma company's acquisition of pre-clinical stage biotech includes mRNA-based research platform

- PMLiVE

Lilly, Vir and GSK’s antibodies reduce viral load by 70% in low-risk COVID-19 patients

The two neutralising antibodies bind to different epitopes of the SARS-CoV-2 spike protein

- PMLiVE

Lilly reports positive data from its phase 3 ulcerative colitis trial

IL-23 blocker mirikizumab helped patients achieve clinical remission in 12-week induction study

- PMLiVE

Sanofi and Translate Bio launch phase 1/2 trial of mRNA-based COVID-19 vaccine

Vaccine candidate induced high antibody levels in preclinical studies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links